RADIOPHARMACEUTICAL
RADIATION ONCOLOGY
CHEMOTHERAPY
NUCLEAR MEDICINE
We provide advanced nuclear medicine services using FDG PET/CT and non-FDG radiotracers for accurate diagnosis and personalized patient care.
Our Services
Our LINAC service delivers precise, high-energy radiation therapy to effectively treat cancer while minimizing exposure to surrounding healthy tissues. This advanced technology ensures accurate, safe, and targeted treatment for better patient outcomes.
Careview produces FDG and specialized non-FDG radiotracers within a GMP-compliant facility, ensuring the highest standards of safety and quality. Our radiopharmaceuticals support advanced diagnostic imaging and therapeutic nuclear medicine applications, delivering reliable solutions for modern healthcare.
Facing cancer is a journey, and Chemotherapy is a powerful tool designed to help you fight back. Our team provides personalized chemo treatments in a supportive environment, focusing not just on treating the illness, but on managing side effects and maintaining your quality of life every step of the way.
Get in Touch and Start Your Care Today
.png)
FBB
LuPSMA-PET/CT
FPSMA-PET/CT
FDG PET/CT
FBB
A procedure that is primarily used for the evaluation of beta amyloid neuritic plaque density. An effective tool to differentiate Alzheimer’s Disease from other forms of Dementia. Khealth Corp. is the only manufacturer in the PH granted with exclusive rights for the production of FBB (Neuraceq®).
FPSMA-PET/CT
Named as a top medical innovation by Cleveland Clinic in 2022. PSMA PET scan has greater sensitivity and can detect prostate cancer metastases sooner, allowing clinicians to better serve patients and make treatment decisions earlier. 800+ patients scanned since 2019.
FDG-PET/CT
A Nuclear Medicine imaging procedure used to detect metabolically active malignant lesions.
A non-invasive approach to accurate diagnosis and staging for the optimal management of cancer patients. 22,000+ patients scanned since 2015.
LuPSMA-PET/CT
Partnered with FPSMA - PET/CT scan, LuPSMA offers a Theranostics approach to treatment of metastatic castration - resistant prostate cancer (mCRPC). Theranostics takes advantage of the specificity of PSMA for PCa cells and has demonstrated promising results in the clinic.